行情

BTX

BTX

Brooklyn Immunotherapeutics Inc
NASDAQ
0.2580
+0.0291
+12.71%
交易中 15:46 09/28 EDT
开盘
0.2289
昨收
0.2289
最高
0.2584
最低
0.2246
成交量
37.24万
成交额
5.86万
52周最高
10.10
52周最低
0.2100
市值
1,517.70万
市盈率(TTM)
-0.1227
分时
5日
1月
3月
1年
5年
Brooklyn ImmunoTherapeutics 披露与 Factor Bioscience 的协议
Brooklyn ImmunoTherapeutics 披露与 Factor Bioscience 的协议
MT Newswires · 09/15 16:58
BTX 简况
Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

微牛提供Brooklyn Immunotherapeutics Inc(NASDAQ-BTX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的BTX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BTX股票基本功能。